News & Events


Monday December 02, 2019

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All

Tuesday November 26, 2019

Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference

Live Audio Webcast will be on December 3, 2019 SAN DIEGO , Nov. 26, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Evercore ISI 2 nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday, Dec. 3, 2019 , in Boston .

Tuesday November 12, 2019

Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia

- Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms - INGREZZA Continues to Be Well Tolerated Through One Year of Treatment SAN DIEGO , Nov.

Tuesday November 05, 2019

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy , Chief Financial Officer, will present at the Credit Suisse 28 th Annual Healthcare

Monday November 04, 2019

Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazine to Treat Chorea in Patients with Huntington's Disease SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.